

## **NEW BIOTECH SYNDEV RX, INC. ESTABLISHES SCIENTIFIC ADVISORY BOARD WITH KEY ANTI-ANGIOGENESIS AND ONCOLOGY LEADERS**

**Cambridge, MA Jan 8, 2008** – SynDevRx™, Inc., a pre-clinical stage biotech company developing the potent anti-angiogenic compound Caplostatin™, announced today the formation of its Scientific Advisory Board. Chairing the SAB is Bruce R. Zetter Ph.D., Chief Scientific Officer of Children's Hospital Boston and VP Research Harvard Medical School. Dr. Zetter brings a wealth of industry knowledge to SynDevRx.

Also serving on the SynDevRx SAB are anti-angiogenesis and oncology experts: Rakesh K. Jain Ph.D., Professor of Tumor Biology at the Massachusetts General Hospital and Harvard Medical School, Dr. Daniel Von Hoff of the University of Arizona and Director of the Translational Genomics Institute (TGen) in Scottsdale, Arizona, and recent appointee to President Bush's National Cancer Advisory Board, and Dr. Roy Herbst Ph.D., Professor of Medicine, Chief of the Section of Thoracic Medical Oncology and Co-Chairman of the Phase I Working Group, Department of Thoracic/Head and Neck Medical Oncology, M. D. Anderson Cancer Center in Houston.

Each SAB member brings unique and extensive hands-on experience with anti-angiogenic drug development to SynDevRx. Dr. Jain conducted key research on Genentech's Avastin® and AstraZeneca's Recentin™ and their mechanisms of action; Dr. Von Hoff has both designed the clinical trials for many FDA approved cancer drugs as well as conducted clinical trials for many drug candidates.

Dr. Herbst's knowledge of this field is unparalleled. He has performed previous Phase I studies on the active moiety in Caplostatin plus numerous other anti-angiogenic agents, including Bevacizumab (Avastin®), PEG-Interferon, ZD6474 (Vandetanib™), Gefitinib (Iressa®), and Erlotinib (Tarceva®). According to Dr. Herbst, "Caplostatin is next-generation anti-angiogenesis technology. It has a well known, very active moiety coupled to a proven tumor-targeting vehicle. Based on the activity we observed in our patients with the active moiety alone, I would expect that Caplostatin should be even more effective, with a better safety profile."

**ABOUT SYNDEV RX, INC.** SynDevRx, Inc. is a biotechnology company founded in 2007 to develop and to commercialize therapeutic compounds in high value diseases with an initial focus in cancer. Our lead compound specifically targets MetAP2 and comes from research by Dr. Judah Folkman, Children's Hospital Boston. Additional information is available at [www.syndevrx.com](http://www.syndevrx.com).

**ABOUT ANGIOGENESIS.** Angiogenesis is the growth of new blood vessels. Dr. Folkman's pioneering work led to the development of the field of angiogenesis research. Uncontrolled angiogenesis is responsible for many diseases affecting more than one billion people worldwide, including cancer, AMD, diabetic retinopathy, arthritis, endometriosis, complications of AIDS, and dozens more major health conditions affecting children and adults.